Spectral Announces Fourth Quarter and Fiscal 2017 Results

Spectral Medical (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31, 2017.

As quoted in the press release:

Revenue for the three months ended December 31, 2017 was $918,000 compared to $806,000 for the same three-month period last year. Revenue for the year ended December 31, 2017 was $3,806,000 compared to $3,545,000 for the prior year, representing an increase of $261,000, or 7%.

Click here to read the full press release.